Days After US Aflibercept Approval, Sandoz Is Hit By Regeneron Lawsuit
Originator Alleges BPCIA Patent Dance Failings Over Filing For Proposed Eylea Biosimilar
Days after Sandoz received US FDA approval for its Enzeevu aflibercept biosimilar rival to Regeneron’s Eylea, the originator has hit the firm with a lawsuit alleging that it failed to follow the “patent dance” set out in the BPCIA biosimilars framework and claiming infringement of multiple patents.
